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1. Introduction 
1.1 Definitions 
Infective endocarditis (IE) is an endovascular, microbial infection of intracardiac structures 
facing the blood, including infections of the large intrathoracic vessels and of intracardiac 
foreign bodies. The early characteristic lesion is a variably sized vegetation, although 
destruction, ulceration, or abscess formation may be seen earlier by echocardiography 
(Habib et al, 2009). 
Prosthetic valve endocarditis (PVE) is classified as early or late, depending on when 
infection is diagnosed: early PVE (within 12 months after surgery) and late PVE (12 months 
or more after surgery).  
Nosocomial IE is defined as an infection occurring > 72 h after admission to the hospital or 
IE acquired in association with a significant invasive procedure performed during a recent 
hospitalization ≤ 8 weeks before the onset of symptoms.  
Persistent infection is defined as a repeat episode of IE caused by the same microorganism 
developing < 1 year after the first episode (Hill et al, 2007). 
1.2 Historical perspective 
The hypothesis of the role of parasites (microorganisms) microscopically observed in 
vegetations and in the cardiac valves of patients with endocarditis was first put forth by 
Winge in Sweden in 1869. Winge's work led Klebs and Rosenbach in Germany to establish, 
between 1878 and 1881, an animal model of experimental endocarditis in which the aortic 
valves of rabbits were perforated with a metallic probe (loaded with septic material) 
introduced through the carotid artery. Ten years after Winge's work, Pasteur emphasized 
the importance of bacteriologic "blood cultures". During the period 1881-1886, Netter and 
Grancher (Pasteur's associates) introduced a method for drawing aseptic blood samples 
from patients with clinical endocarditis and doing bacteriologic blood cultures. In Vienna in 
1885-1886, Orth, Weichselbaum, and Wyssokowitsch further developed Rosenbach's 
procedure of inducing experimental endocarditis by injecting material from a bacterial 
culture into a rabbit's ear vein. The development of an experimental model of endocarditis 
by investigators in the latter part of the nineteenth century provided anatomopathological 
and bacteriologic data that in turn led to a better understanding of IE (Contrepois, 1995). 
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1.3 Epidemiology 
The epidemiological profile of IE has changed substantially over the last few years. In 
industrialized countries, the typical pattern of IE is now an elderly patient with a 
degenerative heart valve disease or with a prosthetic valve or an intracardiac device such as 
a pacemaker or defibrillator leads. Major changes have occurred in the mode of acquisition 
of IE and in its microbiological profile (Thuny et al, 2010). Significant geographical 
variations have been shown. The highest increase in the rate of staphylococcal IE has been 
reported in the USA, where chronic hemodialysis, diabetes mellitus, and intravascular 
devices are the three major factors associated with the development of Staphylococcus aureus 
(S. aureus) endocarditis. In other countries, the main predisposing factor for S. aureus IE may 
be intravenous drug abuse (Habib et al, 2009). 
1.4 Incidence 
The incidence of IE ranges from one country to another within 3–10 episodes/100,000 
person-years. This may reflect methodological differences between surveys rather than true 
variation. Of note, in these surveys, the incidence of IE was very low in young patients but 
increased dramatically with age—the peak incidence was 14.5 episodes/100,000 person-
years in patients between 70 and 80 years old.  
In all epidemiological studies of IE, the male:female ratio is 2:1, although why there is a 
higher proportion of men is poorly understood. Furthermore, female patients may have a 
worse prognosis and undergo valve surgery less frequently than their male counterparts 
(Habib et al, 2009).  
Patients with prosthetic aortic valves are reported to have an incidence of PVE of 0.3 to 1.2 
episodes per 100 patients/year, and approximately 1.4% of patients undergoing aortic valve 
replacement develop PVE during the first postoperative year. 
1.5 Types of infective endocarditis 
IE should be regarded as a set of clinical situations that are sometimes very different from 
each other. In an attempt to avoid overlap, the following four categories of IE must be 
separated according to the site of infection and the presence or absence of intracardiac 
foreign material: left-sided native valve IE, left-sided prosthetic valve IE, right-sided IE, and 
device-related IE (the latter includes IE developing on pacemaker or defibrillator leads with 
or without associated valve involvement).  
With regard to acquisition, the following situations can be identified: community-acquired 
IE, healthcare-associated IE (nosocomial and non-nosocomial), and IE in intravenous drug 
abusers (IVDAs) (Habib et al, 2009). 
1.6 Microbiology 
The microbiology of IE of the aortic valve depends on whether the valve is native or 
prosthetic, and whether the infection is hospital- or community-acquired. 
According to microbiological findings, the following categories are proposed: 
1. IE with positive blood cultures. 
This is the most important category, representing 85% of all IE. Causative microorga-
nisms are most often staphylococci, streptococci, and enterococci (Murdoch et al, 2009). 
a. IE due to streptococci and enterococci. 
Oral (formerly viridans) streptococci form a mixed group of microorganisms, which 
includes species such as S. sanguis, S. mitis, S. salivarius, S. mutans, and Gemella 
www.intechopen.com
 Native and Prosthetic Aortic Valve Endocarditis 
 
95 
morbillorum. Microorganisms of this group are almost always susceptible to 
penicillin. Members of the S. milleri or S. anginosus group (S. anginosus, S. 
intermedius, and S. constellatus) must be distinguished since they tend to form 
abscesses and cause hematogenously disseminated infections, that often require a 
longer duration of antibiotic treatment. Likewise, nutritionally variant “defective“ 
streptococci, recently reclassified into other species (Abiotrophia and Granulicatella), 
should also be distinguished since they are often tolerant to penicillin [minimal 
bactericidal concentration (MBC) much higher than the minimal inhibitory 
concentration (MIC)]. Group D streptococci form the Streptococcus bovis/ 
Streptococcus equinus complex, including commensal species of the human intestinal 
tract, and were until recently gathered under the name of Streptococcus bovis. They, 
like oral streptococci, are usually sensitive to penicillin. Among enterococci, E. 
faecalis, E. faecium, and, to a lesser extent, E. durans, are the three species that cause 
IE. 
b. Staphylococcal IE. 
Traditionally, native valve staphylococcal IE is due to S. aureus, which is most often 
susceptible to oxacillin, at least in community-acquired IE. In contrast, 
staphylococcal prosthetic valve IE is more frequently due to coagulase-negative 
staphylococci (CNS) with oxacillin resistance. However, in a recent study of 1779 
cases of IE collected prospectively in 16 countries, S. aureus was the most frequent 
cause, not only of IE, but also of prosthetic valve IE (Fowler et al, 2005). Conversely, 
CNS can also cause native valve IE (Chu et al, 2004, 2008) especially S. lugdunensis, 
which frequently has an aggressive clinical course. 
2. IE with negative blood cultures because of prior antibiotic treatment. 
This situation arises in patients who received antibiotics for unexplained fever before 
any blood cultures were done and in whom the diagnosis of IE was not considered; 
usually the diagnosis is eventually considered in the face of relapsing febrile episodes 
following antibiotic discontinuation. Blood cultures may remain negative for many 
days after antibiotic cesation, and causative organisms are most often oral streptococci 
or CNS. 
3. IE frequently associated with negative blood cultures. 
They are usually due to fastidious organisms such as nutritionally variant streptococci, 
fastidious Gram-negative bacilli of the HACEK group (H. parainfluenzae, H. aphrophilus, 
H. paraphrophilus, H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium 
hominis, Eikenella corrodens, Kingella kingae, and K. denitrificans), Brucella, and fungi. 
4. IE associated with constantly negative blood cultures. 
They are caused by intracellular bacteria such as Coxiella burnetii, Bartonella, Chlamydia, 
and, as recently demonstrated, Tropheryma whipplei, the agent of Whipple’s disease 
(Richardson et al, 2003). Overall, these account for up to 5% of all IE. Diagnosis in such 
cases relies on serological testing, cell culture, or gene amplification (Habib et al, 2009). 
1.7 Pathophysiology 
Healthy valve endothelium is resistant to colonization and infection by circulating bacteria. 
However, mechanical disruption of the endothelium results in the exposure of underlying 
extracellular matrix proteins, the production of tissue factor, and the deposition of fibrin and 
platelets as a normal healing process. Such nonbacterial thrombotic endocarditis (NBTE) 
facilitates bacterial adherence and infection (Prendergast, 2006). 
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Endothelial damage may result from mechanical lesions induced by turbulent blood flow, 
electrodes or catheters, inflammation, as in rheumatic carditis, or, in the elderly, 
degenerative changes associated with inflammation, micro-ulcers, and microthrombi. 
Endothelial inflammation without valve lesions may also promote IE. Local inflammation 
triggers endothelial cells to express integrins of the b1 family (very late antigen). Integrins 
are transmembrane proteins that can connect extracellular determinants to the cellular 
cytoskeleton. Integrins of the b1 family bind circulating fibronectin to the endothelial surface 
while S. aureus and some other IE pathogens carry fibronectin-binding proteins on their 
surface. Hence, when activated endothelial cells bind fibronectin, they provide an adhesive 
surface for circulating staphylococci. Once adherent, S. aureus trigger their active 
internalization into valve endothelial cells, where they can either persist and escape host 
defenses and antibiotics, or multiply and spread to distant organs. Thus, there are at least 
two scenarios for primary valve infection: one involving a physically damaged 
endothelium, favoring infection by most types of organism, and one occurring on 
physically undamaged endothelium, promoting IE due to S. aureus and other potential 
intracellular pathogens. 
The role of bacteremia has been studied in animals with catheter-induced NBTE. Both the 
magnitude of bacteremia and the ability of the pathogen to attach to damaged valves are 
important. Of note, bacteremia does not occur only after invasive procedures, but also as a 
consequence of chewing and tooth brushing. Such spontaneous bacteremia is low-grade and 
of short duration.  
Classical IE pathogens (S. aureus, Streptococcus spp., and Enterococcus spp.) share the ability to 
adhere to damaged valves, trigger local procoagulant activity, and nurture infected 
vegetations in which they can survive. They are equipped with numerous surface 
determinants that mediate adherence to host matrix molecules present on damaged valves 
(e.g. fibrinogen, fibronectin, platelet proteins) and trigger platelet activation. Following 
colonization, adherent bacteria must escape host defenses.  
Gram-positive bacteria are resistant to complement. However, they may be the target of 
platelet microbicidal proteins (PMPs), which are produced by activated platelets and kill 
microbes by disturbing their plasma membrane. Bacteria recovered from patients with IE 
are consistently resistant to PMP-induced killing, whereas similar bacteria recovered from 
patients with other types of infection are susceptible. Thus, escaping PMP-induced killing is 
a typical characteristic of IE-causing pathogens (Habib et al, 2009). 
2. Diagnosis 
The diagnosis of IE remains a continuous challenge. It must be suspected in the presence of 
a new regurgitant heart murmur, embolic events of unknown origin, sepsis of unknown 
cause, and fever. IE should be suspected if fever is associated with intracardiac prosthetic 
material, a previous history of IE, previous valvular or congenital heart disease, and other 
predisposition or conditions for IE (immunocompromised state, evidence of congestive 
heart failure, conduction disturbance, vascular or immunologic phenomena, unexplained 
focal or non-specific neurological symptoms and signs, etc.). Echocardiography 
(transthoracic, transesophageal) and microbiological diagnosis confirm the diagnosis. 
When diagnosing IE, molecular biology techniques such as PCR are rapid and reliably 
detect fastidious and nonculturable agents in patients, but they have inherent limitations, 
such as they cannot be reliably applied to whole blood samples, they risk contamination, 
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they yield false-negatives because of PCR inhibitors in clinical samples, they are unable to 
provide information about bacterial sensitivity to antimicrobial agents, and they are 
persistently positive despite clinical remission. 
The variability in the clinical presentation of IE requires a diagnostic strategy that is both 
sensitive for disease detection and specific for its exclusion across all forms of the disease. In 
1994, a diagnostic schema, termed the Duke criteria, was proposed. It stratified patients with 
suspected IE into 3 categories: “definite” cases, identified either clinically or pathologically 
(IE proved at surgery or autopsy); “possible” cases (not meeting the criteria for definite IE); 
and “rejected” cases (no pathological evidence of IE at autopsy or surgery, rapid resolution 
of the clinical syndrome with either no treatment or short-term antibiotic therapy, or a firm 
alternative diagnosis) (Durack et al, 1994; Baddour et al, 2005).  
The revised Duke Clinical Diagnostic Criteria for IE were published in 2000, and included 
the following changes: the category “possible IE” was defined as having at least 1 major 
criterion and 1 minor criterion or 3 minor criteria; the minor criterion “echocardiogram 
consistent with IE but not meeting major criterion” was eliminated, given the widespread 
use of transesophageal echocardiography (TEE); bacteremia because of S. aureus was 
considered a major criterion, regardless of whether the infection was nosocomially acquired 
or whether a removable source of infection was present; and positive Q-fever serology was 
changed to a major criterion (Li et al, 2000). 
 
Major Criteria 
Two positive blood cultures for organisms typical of endocarditis 
Three positive blood cultures for organisms consistent with endocarditis 
Serologic evidence of Coxiella burnetii 
Echocardiographic evidence of endocardial involvement: oscillating intracardiac mass on 
a heart valve, on supporting structures, in the path of regurgitant jets, or on 
implanted material without another anatomic explanation, cardiac abscess, new 
dehiscence of prosthetic valve, new valvular regurgitation 
Minor Criteria 
Predisposing heart disorder, intravenous drug abuse, fever ≥ 38°C 
Vascular phenomena: arterial embolism, septic pulmonary embolism, mycotic aneurysm, 
intracranial hemorrhage, conjunctival petechiae, Janeway lesions 
Immunologic phenomena: glomerulonephritis, Osler's nodes, Roth's spots, rheumatoid 
factor 
Microbiologic evidence of infection consistent with but not meeting major criteria 
Serologic evidence of infection with organisms consistent with endocarditis 
For definite clinical diagnosis: 2 major criteria or 1 major criterion and 3 minor criteria or 
5 minor criteria 
For possible clinical diagnosis: 1 major criterion and 1 minor criterion or 3 minor criteria. 
For rejection of diagnosis: Firm alternative diagnosis explaining the findings of IE, 
resolution of symptoms and signs after antimicrobial therapy for ≤ 4 days, no pathologic 
evidence of infective endocarditis found during surgery or autopsy, or failure to meet the 
clinical criteria for possible endocarditis 
Table 1. Revised Duke Clinical Diagnostic Criteria for IE (Adapted from Li et al, 2000) 
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2.1 Clinical features 
Symptoms and signs of IE are nonspecific: fever (94%), malaise (81%), fatigue (66%), loss of 
appetite (52%), dyspnoea (50%), cough (45%), sweating (37%), chills (37%), weight loss (35%), 
myalgia/arthralgia (25%), back pain (9%), vascular phenomena (53%), and splenomegaly 
(31%). Cardiac symptoms or signs (that is, new or altered cardiac murmur, heart failure) are 
recorded in half of the patients. In 36% of the episodes, neurological signs are present. They 
are more common in patients over 55 years old. Intracranial hemorrhages occur in 2%. 
Splenomegaly is found less often in patients over 55 years old than in younger patients. 
Most patients developed hematuria (79%) or anaemia (91%). Patients with anemia are more 
prone to malaise and loss of appetite. Anaemia occurs more often in patients with 
vegetations (Netzer et al, 2000). 
2.2 Microbiological diagnosis 
2.2.1 Blood cultures 
Positive blood cultures remain the cornerstones of diagnosis and provide live bacteria for 
susceptibility testing. Three sets (including at least one aerobic and one anaerobic), each 
containing 10 ml of blood obtained from a peripheral vein using a meticulously sterile 
technique, is virtually always sufficient to identify the usual microorganisms—the 
diagnostic yield of repeated sampling thereafter is low. Sampling from central venous 
catheters should be avoided in view of the high risk of contaminants (false-positives, 
typically staphylococcal) and misleading findings (Habib et al, 2009). Although infective 
endocarditis secondary to anaerobic infection is uncommon, cultures should be sent for both 
aerobic and anaerobic incubation. No evidence suggests that cultures should be taken 
coincident with peaks of temperature, as bacteremia is constant (Beynon et al, 2006). 
2.2.2 Culture-negative infective endocarditis and atypical organisms 
Blood-culture negative IE (BCNIE) occurs in 2.5-31% of all cases of IE, often delaying 
diagnosis and the initiation of treatment, with profound impact on clinical outcome. BCNIE 
arises most commonly as a consequence of prior antibiotic administration, underlying the 
need for withdrawing antibiotics and repeating blood cultures in this situation. An 
increasingly common scenario is infection by fastidious organisms (including Legionella, 
Coxiella, the HACEK group and fungi such as Candida, Histoplasma, and Aspergillus species) 
with limited proliferation under conventional culture conditions, or requiring specialized 
tools for identification. These organisms may be particularly common in IE and affect 
patients with prosthetic valves, indwelling venous lines, pacemakers, renal failure, and 
immunocompromised states. 
2.2.3 Histological/immunological techniques 
Pathological examination of resected valvular tissue or embolic fragments remains the gold 
standard for diagnosing IE and may also guide antimicrobial treatment if the causative 
agent can be identified using special stains or immunohistological techniques. Electron 
microscopy is highly sensitive and may help characterize new microorganisms, but it is time 
consuming and expensive. Coxiella burnetii and Bartonella species may be easily detected 
using serological testing with indirect immunofluorescence or an enzyme-linked 
immunosorbent assay (ELISA), and recent data (Watkin et al, 2006) demonstrate similar 
utility for staphylococci. An immunological analysis of urine may allow the detection of 
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microorganism degradation products, and ELISA detection of Legionella species has been 
described (Helbig et al, 2001). Incorporating these methods into accepted diagnostic criteria 
awaits prospective validation. 
2.2.4 Molecular biology techniques 
The polymerase chain reaction (PCR) allows rapid and reliable detection of fastidious and 
nonculturable agents in patients with IE.  
PCR uses nucleic acid target or signal amplification, alone or in combination with sequence 
analysis. The technique is particularly useful when negative cultures are caused by previous 
administration of antibiotics (as the technique is culture independent) or the presence of a 
fastidious organism and to identify the culprit organism in polymicrobial infection (Beynon 
et al, 2006). 
2.3 Echocardiography 
Echocardiography plays a key role in IE, concerning its diagnosis, the diagnosis of its 
complications, its follow-up under therapy and prognostic assessment. Echocardiography is 
particularly useful for the initial assessment of embolic risk and in decision-making in IE.  
Transesophageal echocardiography (TEE) plays a major role both before surgery and during 
surgery (intraoperative echocardiography). 
Echocardiographic results must be taken into consideration for both the decision to operate 
or not and the choice of the optimal timing for surgery. In all cases, however, the results of 
echocardiographic studies may be interpreted taking into account the clinical features of the 
patient (Habib et al, 2010). 
2.3.1 Transthoracic echocardiography 
Transthoracic echocardiography (TTE) is the initial technique of choice for investigating IE. 
In low-risk patients, a normal transthoracic echocardiogram provides confirmation that 
endocarditis is unlikely and suggests that investigations should be directed elsewhere 
(Beynon et al, 2006). If the clinical suspicion is high, TEE should be used. 
 
 
Fig. 1. Parasternal long axis view from TTE of a native aortic valve vegetation with aortic 
valve rupture 
www.intechopen.com
 Aortic Valve 
 
100 
The sensitivity of TTE ranges from 40% to 63%. There is no better technique for noninvasive 
visualization of vegetations than echocardiography. Overall, the TTE detection rate for 
vegetations in patients with a clinical suspicion of endocarditis averages around 50%. The 
diagnostic yield of the technique in detecting vegetations is influenced by several factors: 
image quality; echogenicity and vegetation size; vegetation location; presence of previous 
valvular disease or valvular prosthesis; experience and skill of the examiner; and pretest 
probability of endocarditis (Evangelista & Gonzalez-Alujas, 2004). 
 
  
Fig. 2. Native aortic valve vegetation (left TTE and right color Doppler ultrasound) 
2.3.2 Transesophageal echocardiography 
In most cases, TTE is sufficient. TEE is indicated when mechanical prosthetic valves are 
present, to detect right-sided lesions and to visualize myocardial abscesses. TEE may be 
considered an invasive procedure, but it is only modestly uncomfortable to the patient, can 
be rapidly done, and is low-risk. It is more sensitive than conventional TTE for detecting 
valvular vegetations. Furthermore, it may detect an unsuspected paravalvular abscess, and 
it correlates well with surgical and pathologic findings. The sensitivity of TEE ranges from 
90% to 100%. 
In high-risk groups, TEE, with its higher sensitivity and specificity, may be needed if the 
TTE is normal and suspicion of IE remains high. TEE is also used to investigate potential 
complications of IE (Beynon et al, 2006). TEE is particularly useful in patients with prosthetic 
valves and for evaluating myocardial invasion. Negative TEE has a negative predictive 
value of over 92% for IE (Mylonakis & Calderwood, 2001). 
2.4 Other imaging technologies 
Other advances in imaging technology have had minimal impact in routine clinical practice. 
Using harmonic imaging has improved study quality, while three-dimensional 
echocardiography and other alternative modes of imaging— computed tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), and radionuclide 
scanning— have yet to be evaluated in IE. Multislice CT has recently been shown to give 
better results than does TEE when evaluating IE-associated valvular abnormalities, 
particularly when assessing the perivalvular extent of abscesses and pseudoaneurysms 
(Habib et al, 2009). 
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2.5 Other tests 
Blood and urine studies: Complete blood count (CBC), electrolytes, creatinine, blood urea 
nitrogen (BUN), glucose, and coagulation panel. Erythrocyte sedimentation rate (ESR), 
while not specific, is elevated in more than 90% of cases. Proteinuria and microscopic 
hematuria are present in approximately 50% of cases. 
Chest X-ray: This has a limited value, although it may demonstrate signs of congestive heart 
failure. Multiple embolic pyogenic abscesses may be visualized. 
Electrocardiography: This may help detect the 10% of patients who develop a conduction 
delay during IE by documenting an increased P-R interval. Nonspecific changes are 
common. A first-degree atrioventricular (AV) block and new interventricular conduction 
delays may signal septal involvement in aortic valve disease; both are poor prognostic 
signs. 
Coronary angiography: This is recommended pre-surgery according to the ESC Guidelines on 
the Management of Valvular Heart Disease in men over 40 years, in post-menopausal 
women, and in patients with at least one cardiovascular risk factor or a history of coronary 
artery disease. Exceptions arise when there are large aortic vegetations that may be 
dislodged during catheterization, or when emergency surgery is necessary. In these 
situations, high-resolution CT may be used to rule out significant coronary artery disease. 
3. Treatment 
The major goals of therapy for IE are to eradicate the infectious agent from the thrombus 
and to address the complications of valvular infection. The latter includes both the 
intracardiac and extracardiac consequences of IE. Some of the effects of IE require surgical 
intervention. 
3.1 Medical treatment 
Successful treatment of IE relies on microbe eradication by antimicrobial drugs. Surgery 
contributes by removing infected material and draining abscesses. Host defenses are of little 
help. This explains why bactericidal regimens are more effective than bacteriostatic therapy, 
both in animal experiments and in humans. 
Aminoglycosides synergize with cell wall inhibitors (i.e. b-lactams and glycopeptides) for 
bactericidal activity and are useful for shortening the duration of therapy (e.g. oral 
streptococci) and eradicate problematic organisms (e.g. Enterococcus spp.). 
One major hindrance to drug-induced killing is bacterial antibiotic tolerance. Tolerant 
microbes are not resistant, i.e. they are still susceptible to growth inhibition by the drug, but 
escape drug-induced killing and may resume growth after treatment discontinuation. 
Slow-growing and dormant microbes display phenotypic tolerance towards most 
antimicrobials (except rifampin to some extent). They are present in vegetations and 
biofilms, e.g. in PVE, and justify the need for prolonged therapy (6 weeks) to sterilize 
infected heart valves fully.  
Some bacteria carry mutations rendering them tolerant during both active growth and 
stationary (dormant) phases. Bactericidal drug combinations are preferred to monotherapy 
against tolerant organisms. 
Drug treatment for PVE should last longer (at least 6 weeks) than that for native-valve 
endocarditis (NVE) (2–6 weeks), but is otherwise similar, except for staphylococcal PVE, for 
which the regimen should include rifampin whenever the strain is susceptible. 
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In NVE needing a valve to be replaced by a prosthesis during antibiotic therapy, the 
postoperative antibiotic regimen should be that recommended for NVE, not for PVE. In both 
NVE and PVE, the duration of treatment is based on the first day of effective antibiotic 
therapy, not on the day of surgery.  
After surgery, a new full course of treatment should start only if valve cultures are positive, 
and the choice of antibiotic should be based on the susceptibility of the latest recovered 
bacterial isolate (Habib et al, 2009). 
3.1.1 Empirical therapy 
IE treatment should be promptly started. The initial choice of empirical treatment depends 
on several considerations: 
• whether the patient has received prior antibiotic therapy or not 
• whether the infection affects a native valve or a prosthesis and, if so, when surgery 
occurred (early vs. late PVE) 
• knowledge of local epidemiology, especially for antibiotic resistance and specific 
genuine culture-negative pathogens. 
NVE and late PVE regimens should cover staphylococci, streptococci, HACEK species, and 
Bartonella spp. Early PVE regimens should cover methicillin-resistant staphylococci and, 
ideally, non-HACEK Gram-negative pathogens (Habib et al, 2009). 
 
Antibiotic Dosage and route Duration 
(weeks) 
Level of 
evidence 
Comments 
Native valves 
Ampicillin-
sulbactam,  
or Amoxicillin-
clavulanate, 
with 
Gentamicin 
12 g/day i.v. in 4 doses 
 
12 g/day i.v. in 4 doses 
 
 
3 mg/kg/day i.v. or i.m. in 
2 or 3 doses 
4-6 
 
4-6 
 
 
4-6 
II C 
 
II C 
Patients with BCNIE 
should be treated in 
consultation with an 
infectious disease 
specialist. 
Vancomycin 
with 
Gentamicin 
with 
Ciprofloxacin 
30 mg/kg/day i.v. in 2 
doses 
3 mg/kg/day i.v. or i.m. in 
2 or 3 doses 
1000 mg/day orally in 2 
doses or 800 mg/day i.v. in 
2 doses 
 
4-6 
 
4-6 
 
4-6 
II C For patients unable to 
tolerate ǃ-lactams 
Ciprofloxacin is not 
uniformly active on 
Bartonella spp. Adding 
doxycycline is an option 
if Bartonella spp. is likely. 
Prosthetic valves (early, < 12 months post-surgery) 
Vancomycin 
with 
Gentamicin 
with 
Rifampin 
30 mg/kg/day i.v. in 2 
doses 
3 mg/kg/day i.v. or i.m. in 
2 or 3 doses 
1200 mg/day orally in 2 
doses 
6 
 
2 
 
 
II C If no clinical response, 
surgery and maybe 
extending the antibiotic 
spectrum to Gram-
negative pathogens 
must be considered. 
Prosthetic valves (late, ≥ 12 months post-surgery) 
Same as for native valves 
Table 2. Proposed antibiotic regimens for initial empirical treatment of IE (before or without 
pathogen identification) (Adapted from Habib et al, 2009) 
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3.1.2 Penicillin-susceptible oral streptococci and group D streptococci 
The cure rate is expected to be > 95%. In uncomplicated cases, short-term (2-week) therapy 
can be administered by combining penicillin or ceftriaxone with gentamicin or netilmicin. 
Ceftriaxone alone or combined with gentamicin or netilmicin given once a day is 
particularly convenient for outpatient therapy. Patients allergic to b-lactams should receive 
vancomycin. Teicoplanin has been proposed as an alternative and requires loading doses (6 
mg/kg/12 h for 3 days) followed by 6–10 mg/kg/day. Loading is critical because the drug 
is highly bound to serum proteins and penetrates slowly into vegetations. 
3.1.3 Penicillin-resistant oral streptococci and group D streptococci 
Such resistant streptococci are increasing. Antibiotic therapy for penicillin-resistant and 
penicillin-susceptible oral streptococci is qualitatively similar. However, in penicillin-
resistant cases, aminoglycoside treatment may be prolonged to 3–4 weeks, and short-term 
therapy regimens are not recommended. Little experience exists with highly resistant 
isolates (MIC > 4 mg/L)—vancomycin might be preferred in such circumstances. 
3.1.4 Streptococcus pneumoniae, b-hemolytic streptococci (groups A, B, C, and G) 
IE due to S. pneumoniae has become rare since the introduction of antibiotics. It is associated 
with meningitis in up to 30% of cases, which requires special consideration in penicillin-
resistant cases. Treatment is similar to that of oral streptococci, except for the use of short-
term (2-week) therapy, which has not been formally investigated. In cases with meningitis, 
penicillin must be avoided because it poorly penetrates the cerebrospinal fluid, and should 
be replaced with ceftriaxone or cefotaxime alone or cefotaxime combined with vancomycin. 
IE due to group A, B, C, or G streptococci—including the S. milleri group (S. constellatus, S. 
anginosus, and S. intermedius)—is relatively rare. Group A streptococci are uniformly 
susceptible to b-lactams, whereas other serogroups may display resistance. IE due to group 
B streptococci was once associated with the peripartum period, but now occurs in adults, 
especially the elderly. Group B, C, and G streptococci and S. milleri produce abscesses and 
thus may require adjunctive surgery. The mortality of group B PVE is very high, and cardiac 
surgery is recommended. Antibiotic treatment is similar to that of oral streptococci, except 
that short-term therapy is not recommended. 
3.1.5 Nutritionally variant streptococci 
Nutritionally variant streptococci produce IE with a protracted course, which is associated 
with higher rates of complications and treatment failure (up to 40%), possibly due to 
delayed diagnosis and treatment. Antibiotic recommendations include penicillin, 
ceftriaxone, or vancomycin for 6 weeks, combined with an aminoglycoside for at least the 
first 2 weeks. 
3.1.6 S. aureus and coagulase-negative staphylococci 
S. aureus is usually responsible for acute and destructive IE, whereas CNS produce more 
protracted valve infections (except S. lugdunensis and some cases of S. capitis). S. aureus PVE 
carries a very high risk of mortality (> 45%) and often requires early valve replacement. 
Other differences in comparison with NVE include the overall duration of therapy, 
prolonged additional use of aminoglycosides, and the addition of rifampin. Although the 
level of evidence is poor, adding rifampin in the treatment of staphylococcal PVE is 
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standard practice, although treatment may be associated with microbial resistance, 
hepatotoxicity, and drug interactions. 
 
Antibiotic Dosage and route Duration (weeks) Level of evidence 
Native valves 
Methicillin-susceptible staphylococci 
Flucloxacillin 
or  
Oxacillin 
with  
Gentamicin 
12 g/day i.v. in 4-6 doses 
 
 
 
3 mg/kg/day i.v. or i.m. in 2 or 3 
doses 
Pediatric doses: 
Oxacillin or flucloxacillin 200 
mg/kg/day i.v. in 4-6 equally 
divided doses. 
Gentamicin 3 mg/kg/day i.v. or. i.m. 
in 3 equally divided doses. 
4– 6 
 
 
 
3– 5 days 
I B 
Penicillin–allergic patients or methicillin–resistant staphylococci 
Vancomycin 
with 
Gentamicin 
30 mg/kg/day i.v. in 2 doses 
 
3 mg/kg/day i.v. or i.m. in 2 or 3 
doses 
Pediatric doses: 
Vancomycin 40 mg/kg/day i.v. in 2-
3 equally divided doses. 
4– 6 
 
3– 5 days 
I B 
Prosthetic valves 
Methicillin–susceptible staphylococci: 
Flucloxacillin, 
or 
Oxacillin 
with 
Rifampin 
and 
Gentamicin 
12 g/day i.v. in 4-6 doses 
 
 
 
1200 mg/day i.v. orally in 2 doses 
 
3 mg/kg/day i.v. in 2 or 3 doses 
Pediatric doses: 
Oxacillin and flucloxacillin as above. 
Rifampin 20 mg/kg/day i.v. or 
orally in 3 equally divided doses. 
≥ 6 
 
 
 
≥ 6 
 
2 
I B 
Penicillin–allergic patients and methicillin-resistant staphylococci: 
Vancomycin 
with 
Rifampin 
and 
Gentamicin 
30 mg/kg/day i.v. in 2 doses 
 
1200 mg/day i.v. or orally in 2 doses 
 
3 mg/kg/day i.v. or i.m. in 2 or 3 
doses 
Pediatric doses: As above. 
≥ 6 
 
≥ 6 
 
2 
I B 
Table 3. Antibiotic treatment of IE due to Staphylococcus spp. (Habib et al, 2009) 
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3.1.7 Methicillin-resistant and vancomycin-resistant staphylococci 
MRSA produce low-affinity plasma-binding protein (PBP) 2A, which confers cross-
resistance to most b-lactams. They are usually resistant to multiple antibiotics, leaving only 
vancomycin to treat severe infections. However, vancomycin-intermediate S. aureus (VISA) 
(MIC 4–16 mg/L) and hetero-VISA (MIC ≤ 2 mg/L, but with subpopulations growing at 
higher concentrations) have emerged worldwide, and are associated with IE treatment 
failures (Howden et al, 2006). Moreover, some highly vancomycin-resistant S. aureus have 
been isolated from infected patients in recent years, requiring new approaches to treatment. 
New lipopeptide daptomycin (6 mg/kg/day i.v.) was recently approved for S. aureus 
bacteremia and right-sided IE (Fowler et al, 2006). Observational studies suggest that 
daptomycin might also be considered in left-sided IE and may overcome methicillin and 
vancomycin resistance (Levine & Lamp, 2007). Importantly, daptomycin needs to be 
administered in appropriate doses to avoid further resistance. Other choices include newer 
b-lactams with relatively good PBP2A affinity, quinupristin-dalfopristin with or without b-
lactams, b-lactams plus oxazolidinones, and b-lactams plus vancomycin. Such cases warrant 
collaborative management with an infectious diseases specialist. 
3.1.8 Enterococcus spp. 
Enterococcal IE is primarily caused by E. faecalis (90% of cases) and, more rarely, by E.  
faecium or other species. They pose two major problems. First, enterococci are highly tolerant 
to antibiotic-induced killing, and eradication requires prolonged administration (up to 6 
weeks) of synergistic bactericidal combinations of cell-wall inhibitors with aminoglycosides. 
Secondly, they may be resistant to multiple drugs, including aminoglycosides, b-lactams 
(via PBP5 modification and sometimes b-lactamases), and vancomycin. Fully penicillin-
susceptible strains (penicillin MIC ≤ 8 mg/L) are treated with penicillin or ampicillin (or 
amoxicillin) combined with gentamicin. Ampicillin (or amoxicillin) might be preferred since 
MICs are 2–4 times lower. Prolonged courses of gentamicin require regular monitoring of 
serum drug levels and renal and vestibular function. One study reported success with short-
course administration of aminoglycosides (2–3 weeks) in 74 (81%) of 91 episodes of 
enterococcal IE (Olaison & Schadewitz, 2002). This option might be considered in cases 
where prolonged treatment is limited by toxicity. 
High-level gentamicin resistance is frequent in both E. faecalis and E. faecium. An 
aminoglycoside MIC > 500 mg/L is associated with the loss of bactericidal synergism with 
cell-wall inhibitors, and aminoglycosides should not be used in such conditions. 
Streptomycin may remain active in such cases and is a useful alternative. An additional 
recently described (Gavalda et al, 2007) option against gentamicin-resistant E. faecalis is the 
combination of ampicillin and ceftriaxone, which synergize by inhibiting complementary 
PBPs. Otherwise, more prolonged courses of b-lactams or vancomycin should be 
considered. B-Lactam and vancomycin resistance are observed primarily in E. faecium. Since 
dual resistance is rare, b-lactam might be used against vancomycin-resistant strains, and 
vice versa. Varying results have been reported with quinupristin–dalfopristin, linezolid, 
daptomycin, and tigecycline. Again, these situations require the expertise of an infectious 
diseases specialist. 
3.1.9 Gram-negative bacteria 
HACEK-related species: HACEK Gram-negative bacilli are fastidious organisms needing 
specialized investigations. Because they grow slowly, standard MIC tests may be difficult to 
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Pathogens Proposed therapy Treatment outcome 
Brucella spp. Doxycycline (200 mg/24 h) 
plus cotrimoxazole (960 mg/12 h) 
plus rifampin (300-600 mg/24 h) 
for ≥ 3 months orally (Adding 
streptomycin (15 mg/kg/24 h in two 
doses) for the first few weeks is 
optional) 
Treatment success defined as 
an antibody titer < 1:60 
Coxiella 
burnetii 
(agent of Q 
fever) 
Doxycycline (200 mg/24 h) plus 
hydroxychloroquine (200-600 mg/24 h) 
orally or 
Doxycycline (200 mg/24 h) plus 
quinolone (ofloxacin, 400 mg/24 h) 
orally (>18 months treatment) 
Doxycycline plus hydroxychloroquine 
(with monitoring of serum 
hydroxychloroquine levels) is superior 
to doxycycline alone and to 
doxycycline + fluoroquinolone 
Treatment success defined as 
anti-phase I IgG titer < 1:200, 
and IgM titers < 1:50 
Bartonella spp. Ceftriaxone (2 g/24 h) or ampicillin (or 
amoxicillin) (12 g/24 h) i.v. or 
Doxycycline (200 mg/24 h) orally for 6 
weeks plus Gentamicin (3 mg/24 h) or 
netilmicin i.v. (for 3 weeks) 
Treatment success expected 
in 
≥ 90% 
Legionella spp. Erythromycin (3g/24h) i.v. for 2 weeks, 
then orally for 4 weeks plus Rifampin 
(300-1200 mg/24h) or 
Ciprofloxacin (1.5 g/24 h) orally for 6 
weeks 
Optimal treatment 
unknown. 
Because of high 
susceptibility, quinolones 
should probably be 
included. 
Mycoplasma 
spp. 
Newer fluoroquinolones (> 6 months 
treatment) 
Newer fluoroquinolones are more 
potent than ciprofloxacin against 
intracellular pathogens such as 
Mycoplasma spp., Legionella spp., and 
Chlamydia spp. 
Optimal treatment 
unknown. 
Tropheryma 
whipplei (agent 
of Whipple’s 
disease 
Cotrimoxazole 
Penicillin (1.2 MU/24 h) and 
streptomycin (1 g/24 h) i.v. for 2 weeks, 
then Cotrimoxazole orally for 1 year or 
Doxycycline (200 mg/24 h) plus 
Hydroxychloroquine (200-600 mg/24 h) 
orally for ≥ 18 months 
Long-term treatment, 
optimal duration unknown. 
Table 4. Antibiotic treatment of BCNIE. (Adapted from Brouqui & Raoult, 2001) 
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interpret. Some HACEK group bacilli produce b-lactamases, and ampicillin is therefore no 
longer the first-line option. Conversely, they are susceptible to ceftriaxone, other third-
generation cephalosporins, and quinolones—the standard treatment is ceftriaxone 2 g/day 
for 4 weeks. If they do not produce b-lactamase, intravenous ampicillin (12 g/day i.v. in 
four or six doses) plus gentamicin (3 mg/kg/day in two or three doses) for 4 weeks is an 
option. Ciprofloxacin (2 x 400 mg/day i.v. or 1000 mg/day orally) is a less well-validated 
option (Das et al, 1997).  
Non-HACEK species: Recommended treatment is early surgery plus long-term (≥ 6 weeks) 
therapy with bactericidal combinations of b-lactams and aminoglycosides, sometimes with 
additional quinolones or cotrimoxazole. In vitro bactericidal tests and monitoring serum 
antibiotic concentrations may be helpful. Because of their rarity and severity, these 
conditions should be managed with the input of an infectious diseases specialist (Habib et 
al, 2009). 
3.1.10 Blood culture-negative IE 
Due to the lack of large series, the optimal duration of the treatment of IE due to these 
pathogens is unknown. The presented durations are based on selected case reports. 
Treating Whipple IE remains highly empirical. Successes have been reported with long-term 
(> 1 year) cotrimoxazole therapy. Ǆ-Interferon is protective in intracellular infections and has 
been proposed as adjuvant therapy in Whipple’s disease. 
3.1.11 Fungi 
Fungi are most frequently observed in PVE and in IE affecting IVDAs and 
immunocompromised patients. Candida and Aspergillus spp. predominate, the latter resulting 
in BCNIE. Mortality is very high (> 50%), and treatment necessitates dual antifungal 
administration and valve replacement. Most cases are treated with various forms of 
amphotericin B with or without azoles, although recent case reports describe successful 
therapy with the new echinocandin caspofungin (Garzoni et al, 2007; Lye et al, 2005). 
Suppressive treatment with oral azoles is often maintained long term and sometimes for life. 
3.2 Surgical treatment 
Surgery has an established role in the management of IE across a wide range of patients, a 
role that appears poised to increase as the complexity of patients with this difficult condition 
rises and the benefits of earlier surgery emerge. 
Contemporary data in Europe indicate that surgical treatment is used in approximately half 
of patients with IE because of severe complications. Reasons to consider early surgery in the 
active phase, i.e. while the patient is still receiving antibiotic treatment, are to avoid 
progressive heart failure (HF) and irreversible structural damage caused by severe infection 
and to prevent systemic embolisms. On the other hand, surgical therapy during the active 
phase of the disease is associated with significant risk. 
Surgery performed very early may improve survival in patients with the most severely 
complicated IE. However, a greater risk of relapses and postoperative valvular dysfunctions 
should be expected with very early surgery (Thuny et al, 2009). 
3.2.1 Indications for surgery in IE 
- Congestive HF: Congestive HF caused by severe aortic regurgitation or, more rarely, by 
valve obstruction caused by vegetations, severe acute aortic regurgitation with 
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echocardiographic signs of elevated left ventricular end-diastolic pressure or significant 
pulmonary hypertension, congestive HF as a result of prosthetic dehiscence or 
obstruction; 
- Periannular extension: Most patients with abscess formation or fistulous tract formation; 
- Systemic embolism: Recurrent emboli despite appropriate antibiotic therapy, large 
vegetations (> 10 mm) after 1 or more clinical or silent embolic events after the initiation 
of antibiotic therapy, large vegetations and other predictors of a complicated course, 
very large vegetations (> 15 mm) without embolic complications, especially if valve-
sparing surgery is likely (remains controversial); 
- Cerebrovascular complications: Silent neurological complication or transient ischemic 
attack and other surgical indications, ischemic stroke and other surgical indications, 
provided that cerebral hemorrhage has been excluded and neurological complications 
are not severe (e.g. coma); 
- Persistent sepsis: Fever or positive blood cultures persisting for > 5 to 7 days despite an 
appropriate antibiotic regimen, assuming that vegetations or other lesions requiring 
surgery persist and that extracardiac sources of sepsis have been excluded; 
- Relapsing IE: Especially when caused by organisms other than sensitive streptococci or 
in patients with prosthetic valves; 
- Difficult organisms: S. aureus IE involving a prosthetic valve and most cases involving 
a left-sided native valve, IE caused by other aggressive organisms (Brucella, 
Staphylococcus lugdunensis), IE caused by multiresistant organisms (e.g. methicillin-
resistant S. aureus or vancomycin-resistant enterococci) and rare infections caused by 
Gram-negative bacteria, Pseudomonas aeruginosa IE, fungal IE, Q fever IE, and other 
relative indications for intervention; 
- PVE: Virtually all cases of early PVE, virtually all cases of PVE caused by S. aureus, late 
PVE with HF caused by prosthetic dehiscence or obstruction (Prendergast & Tornos, 
2010). 
The three main indications for early surgery in IE are: HF, uncontrolled infection, and 
prevention of embolic events. 
3.2.2 Timing of surgery 
- Emergency surgery (within 24 hours): NVE or PVE and severe congestive HF or 
cardiogenic shock caused by: acute valvular regurgitation, severe prosthetic 
dysfunction (dehiscence or obstruction), fistula into a cardiac chamber or the pericardial 
space 
- Urgent surgery (within days): NVE with persistent congestive HF, signs of poor 
hemodynamic tolerance, or abscess; PVE with persistent congestive heart failure, signs 
of poor hemodynamic tolerance, or abscess; PVE caused by staphylococci or Gram-
negative organisms, large vegetation (> 10 mm) with an embolic event, large vegetation 
(> 10 mm) with other predictors of a complicated course, very large vegetation (> 15 
mm), especially if conservative surgery is available, large abscess or periannular 
involvement with uncontrolled infection; 
- Early elective surgery (during the in-hospital stay): Severe aortic regurgitation with 
congestive HF and good response to medical therapy, PVE with valvular dehiscence or 
congestive heart failure and good response to medical therapy, presence of abscess or 
periannular extension, persistent infection when extracardiac focus has been excluded, 
fungal or other infections resistant to medical cure (Prendergast & Tornos, 2010). 
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3.2.3 Surgical approach and techniques 
The two primary objectives of surgery are the total removal of infected tissue and the 
reconstruction of cardiac morphology, including repair or replacement of the affected valve. 
The mode of surgery (replacement versus repair) or type of prosthesis used (mechanical 
versus biological) has no influence on operative mortality, although repair techniques, when 
applicable, offer long-term advantages, including a reduced risk of late complications 
(notably, recurrent IE) and obviate the need for lifelong anticoagulation medication. 
Homografts offer a reduced risk of recurrent infection in aortic IE, although their use 
remains controversial owing to a higher risk of late complications. Cardiac transplantation 
may be considered in extreme cases with recurrent PVE (Pavie, 2006). 
Where infection is confined to the valve cusps or leaflets, any method of repairing or 
replacing the valve may be used. However, valve repair is favored whenever possible. 
Perforations in a single valve cusp or leaflet may be repaired with an autologous 
glutaraldehyde-treated or bovine pericardial patch. 
In complex cases with locally uncontrolled infection, total excision of infected and 
devitalized tissue should be followed by valve replacement and repair of associated defects 
to secure valve fixation. Mechanical and biological prostheses have similar operative 
mortality (Edwards et al, 1998). The use of foreign material should be kept to a minimum. 
Small abscesses can be closed directly. Radical resection of the abscess is essential. The 
general consensus is that an aortic valve homograft is the ideal conduit for an aortic root 
abscess, but that it is not a substitute for radical extirpation of the abscess and all inflamed 
tissue (David et al, 2007). 
In aortic IE, replacing the aortic valve with a mechanical or biological prosthesis is the 
technique of choice. Using cryopreserved or sterilized homografts has been suggested to 
reduce the risk of persistent or recurrent infection (Lopes et al, 2007). However, mechanical 
prostheses and xenografts compare favorably, and with improved durability. Homografts or 
stentless xenografts may be preferred in PVE or in cases where there is extensive aortic root 
destruction with aorto-ventricular discontinuity (Sabik et al, 2002). A tailored tubular 
Dacron graft to concomitantly reconstruct the left ventricular outflow tract and replace the 
aortic root is a useful and safe operative technique for patients with destroyed aorto-
ventricular junction. 
A monoblock aorto-mitral homograft has been suggested as a surgical option for extensive 
bivalvular IE (Obadia et al, 2006).  
3.2.4 Operative mortality and morbidity 
Perioperative mortality and morbidity vary according to the type of infective agent, the 
extent of destruction of cardiac structures, the degree of left ventricular dysfunction, and the 
patient’s hemodynamic condition at the time of surgery. Currently, operative mortality in IE 
lies between 5% and 15%. 
The outcomes of PVE are worse than those of NVE. The main reason the operative mortality 
for PVE is higher than that for NVE is the complexity of the operation and the fact that it is 
often associated with a paravalvular abscess (David et al, 2006). 
When surgery must be done within the first week of antimicrobial therapy, a recent study 
showed that in-hospital mortality is 15%, with risks of recurrence and non-infective 
postoperative valvular dysfunction of 12% and 7%, respectively (Thuny et al, 2008). 
In less complex cases, where disease is limited to the valve structures alone allowing 
complete excision of the infected tissue, mortality should be similar to routine valve surgery. 
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The cause of death is often multifactorial, but the main reasons are multiorgan failure, HF, 
intractable sepsis, coagulopathy, and stroke. 
3.2.5 Postoperative complications 
Immediate postoperative complications are relatively common. Among the most frequent 
are severe coagulopathy requiring treatment with clotting factors, re-exploration of the chest 
for bleeding or tamponade, acute renal failure requiring hemodialysis, stroke, low cardiac 
output syndrome, pneumonia, and atrioventricular block following radical resection of an 
aortic root abscess with a need for pacemaker implantation. A preoperative ECG 
demonstrating left bundle branch block predicts the need for a postoperative permanent 
pacemaker. 
3.3 Prophylaxis for IE 
The European Society of Cardiology Guideline proposes limiting antibiotic prophylaxis to 
patients with the highest risk of IE undergoing the highest risk dental procedures. Patients 
with the highest risk of IE are patients with a prosthetic valve or a prosthetic material used 
for cardiac valve repair, patients with previous IE, patients with congenital heart disease, in 
particular those with complex cyanotic heart disease and those who have postoperative 
palliative shunts, conduits, or other prostheses. Procedures at risk involve the manipulation 
of the gingival or periapical region of teeth or perforation of the oral mucosa, including 
scaling and root canal procedures.  Good oral hygiene and regular dental review are very 
important for reducing the risk of IE. Aseptic measures are mandatory during venous 
catheter manipulation and during any invasive procedures in order to reduce the rate of 
healthcare-associated IE (Habib et al, 2009). 
The American Heart Association Guideline includes cardiac transplant recipients who 
develop cardiac valvulopathy on the list of patients with the highest risk of IE. It also 
recommends prophylaxis for procedures on respiratory tract or infected skin, skin 
structures, or musculoskeletal tissue only for patients with underlying cardiac conditions 
associated with the highest risk of adverse outcome from IE (Wilson et al, 2007). 
An antibiotic for prophylaxis should be given in a single dose 30-60 minutes before the 
procedure. Amoxicillin is the preferred choice for oral therapy because it is well absorbed in 
the GI tract and provides high and sustained serum concentrations. For individuals who are 
allergic to penicillin or amoxicillin, the use of cephalexin or another first-generation oral 
cephalosporin, clindamycin, azithromycin, or clarithromycin is recommended. Because of 
possible cross-reactions, a cephalosporin should not be given to patients with a history of 
anaphylaxis, angioedema, or urticaria after treatment with any form of penicillin, including 
ampicillin or amoxicillin (Habib et al, 2009; Wilson et al, 2007). 
4. Complications of IE 
4.1 Heart failure 
HF is the most frequent complication of IE and represents the most frequent indication for 
surgery in IE. HF is observed in 50–60% of cases overall and is more often present when IE 
affects the aortic (29%) rather than the mitral (20%) valve (Baddour et al, 2005). HF can be 
caused by severe aortic regurgitation, intracardiac fistulae, or, more rarely, by valve 
obstruction, when a large vegetation partially obstructs the valve orifice.  
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Clinical presentation of HF may include severe dyspnea, pulmonary edema, and 
cardiogenic shock. In addition to clinical findings, TTE is crucially important for the initial 
evaluation and follow-up. Echocardiography is also of more general value for hemodynamic 
assessment of valvular dysfunction, measurement of pulmonary artery pressure, and 
assessment and monitoring of left ventricular systolic function and left and right heart 
filling pressures. Brain natriuretic peptide (NT-proBNP) is potentially useful for diagnosing 
and monitoring HF in IE. 
HF may progress from mild to severe during treatment, and two-thirds of these cases occur 
during the active phase of the disease. Moderate-to-severe HF is the most important 
predictor of in-hospital and 6-month mortality (Baddour et al, 2005).  
4.2 Uncontrolled infection 
Uncontrolled infection is the second most frequent cause for surgery and encompasses 
persisting infection (> 7–10 days), infection due to resistant organisms, and locally 
uncontrolled infection.  
Uncontrolled infection is most frequently related to perivalvular extension (the most 
frequent cause, associated with a poor prognosis and a high likelihood of the need for 
surgery) or difficult-to-treat organisms, such as fungi, multiresistant organisms, e.g. MRSA 
or vancomycin-resistant enterococci, and also in the rare infections caused by Gram-
negative bacteria. 
Signs of locally uncontrolled infection include increasing vegetation size, abscess formation, 
false aneurysms, or the creation of fistulae. Persistent fever is also usually present. 
Unless severe comorbidity exists, the presence of locally uncontrolled infection indicates 
early surgery in patients with NVE (Habib et al, 2009). 
4.3 Systemic embolism 
Embolic events are a frequent and life-threatening complication of IE related to the 
migration of cardiac vegetations. It has been reported to occur in 13% to 49% of cases. The 
brain and spleen are the most frequent sites of embolisms in aortic IE.  
Embolisms after adequate antimicrobial treatment are frequent, and most embolisms occur 
within the first two weeks of therapy. Embolisms before antimicrobial therapy are a risk 
factor for embolisms after antimicrobial therapy has begun. Controlling infection is 
important for preventing embolisms. The benefits of surgery to prevent embolisms are 
greatest during the first week of antibiotic therapy, when embolic risk peaks. 
Several factors are associated with increased risk of embolisms: the size and mobility of 
vegetations, the location of the vegetation, an increase or decrease in the size of the 
vegetation under antibiotic therapy, particular microorganisms (staphylococci, Streptococcus 
bovis, Candida spp.), previous embolisms, multivalvular IE, and biological markers. 
The risk of embolization seems to increase with increasing vegetation size, and this is 
particularly significant in staphylococcal endocarditis (Vilacosta et al, 2002). 
4.4 Neurological complications 
Neurologic events develop in 20–40% of all patients with IE. 
Neurologic complications of IE most commonly occur as a result of embolization from 
endocardial vegetation, with the resultant occlusion of cerebral arteries. An ischemic or 
hemorrhagic stroke or a transient ischemic attack (TIA) can then develop. The dissemination 
of infected embolic material into cerebral or meningeal vessels may also lead to meningitis 
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or brain abscesses. More nonspecific neurologic manifestations associated with IE include 
headache, seizures, and toxic encephalopathy. Cerebral hemorrhage is the most dramatic, 
though fortunately rare, neurologic complication of IE. It can be caused by a rupture of a 
mycotic aneurysm even months to years after the IE has been cured. 
Neurologic manifestations of IE occur mainly before antimicrobial treatment has begun, 
thus reinforcing the belief that rapidly diagnosing and initiating antimicrobial therapy may 
still be the most effective means of preventing neurologic complications (Heiro et al, 2000). 
After a first neurological event, most patients still have an indication for surgery that is 
generally not contraindicated. 
4.5 Infectious aneurysms 
Infectious (mycotic) aneurysms (IAs) result from septic arterial embolisms to the 
intraluminal space or vasa vasorum, or from the subsequent spread of infection through the 
intimal vessels. An intracranial location is most frequent, and the reported frequency of  
2–4% (Corr et al, 1995) is probably an underestimate since some IAs are clinically silent. 
The most important sequelae of these aneurysms is bleeding, which can occur days, weeks, 
months, or, rarely, years after successful therapy for the underlying IE. Cerebral mycotic 
aneurysms tend to occur in the more distal portions of the middle cerebral artery near the 
surface of the brain involving the secondary and tertiary branches. This characteristic 
pattern helps to separate them clinically from berry aneurysms, which tend to occur near the 
base of the brain and the circle of Willis. 
4.6 Acute renal failure 
Acute renal failure is a common complication of IE, which occurs in 30% of patients and 
predicts a poor prognosis. Causes of acute renal failure are often multifactorial and include 
the following: immune complex and vasculitic glomerulonephritis, renal infarction, 
hemodynamic impairment in cases with HF or severe sepsis, or, after cardiac surgery, 
antibiotic toxicity, notably related to aminoglycosides, vancomycin, and even high-dose 
penicillin, nephrotoxicity of contrast agents used for imaging (Majumdar et al, 2000).  
Hemodialysis may be required in some patients, but acute renal failure is often reversible. 
4.7 Rheumatic complications 
Musculoskeletal symptoms (arthralgia, myalgia, back pain) are frequent during IE, and 
rheumatic complications may be the first manifestations of the disease. Peripheral arthritis 
occurs in 14% and spondylodiscitis in 3–15% of cases.  
Vertebral osteomyelitis is a known but rare complication of IE, occurring most frequently in 
patients with S. aureus infection. Acute septic arthritis involving 2 or more joints should 
raise a suspicion of IE (Speechly-Dick & Swanton, 1994). 
4.8 Splenic abscess 
Although splenic emboli are common, splenic abscess is rare. Persistent or recurrent fever 
and bacteremia suggest the diagnosis, and these patients should be evaluated using 
abdominal CT, MRI, or ultrasound. Treatment consists of appropriate antibiotic regimens. A 
splenectomy may be considered for splenic rupture or large abscesses that respond poorly 
to antibiotics alone, and should be done before valvular surgery, unless the latter is urgent. 
Percutaneous drainage is an alternative for high-risk surgical candidates. (Chou et al, 1992) 
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4.9 Myocarditis, pericarditis 
Cardiac failure may also be due to myocarditis, which is frequently associated with abscess 
formation. Regional myocardial infarction may be caused by coronary embolisms or 
compression. Ventricular arrhythmias may indicate myocardial involvement and imply a 
poor prognosis. Myocardial involvement is best assessed using TTE. 
Pericarditis may be associated with an abscess, myocarditis, or bacteremia, often as a result 
of S. aureus infection. Purulent pericarditis is rare and may necessitate surgical drainage. 
Rarely, ruptured pseudoaneurysms or fistulae may communicate with the pericardium, 
with dramatic and often fatal consequences (Sexton & Spelman, 2002). 
5. Outcome and long-term prognosis 
The prognosis of aortic valve endocarditis depends largely on when the disease is 
diagnosed, which microorganism is involved, and how promptly it is treated. 
Patients with PVE have a more serious prognosis than patients with NVE. 
Late complications occurring after the initial infection contribute to the poor prognosis of IE. 
Following in-hospital treatment, the main complications include a recurrence of infection, 
HF, a need for valve surgery, and death. 
The risk of recurrence among survivors of IE varies between 2.7% and 22.5%. There are two 
types of recurrence: relapse and reinfection. The term “relapse” refers to a repeat episode of 
IE caused by the same microorganism as the previous episode. In contrast, “reinfection” is 
used primarily to describe infection with a different microorganism (Chu et al, 2005). 
Relapses are most often due to an insufficient duration of the original treatment, a 
suboptimal choice of initial antibiotics, and a persistent focus of infection (e.g. a 
periprosthetic abscess). 
Progressive HF can occur as a consequence of valve destruction, even when the infection is 
healed. After the completion of treatment, recommendations for surgery follow conventional 
guidelines. 
Following the in-hospital phase, principal factors that determine long-term mortality are 
age, comorbidity, and HF, particularly when surgery has not been done, which suggests that 
long-term mortality is related to the underlying conditions rather than to the IE itself. 
A high early surgery rate is related to good long-term results and does not increase in-
hospital mortality. Medical treatment, however, also offers favorable long-term results in 
cases of responsive IE where poor prognostic factors are absent (Bishara et al, 2001). 
The IE prognosis is not uniform. Mortality is high during the initial phase, but after one 
year, the risk of dying is low, although still above that of the general population. Part of the 
risk is probably the direct consequence of IE, but part is due to the course of the underlying 
heart disease (Delahaye et al, 1995). 
6. Conclusions 
IE is a changing disease with predisposing risk factors, etiology, manifestations, and 
therapeutics in continuous evolution. 
Although modern antibiotic and surgical treatments have substantially improved outcomes 
in recent decades, IE remains a life-threatening disease. As mortality during the active phase 
of the infection has declined, long-term morbidity and mortality caused by late sequelae 
www.intechopen.com
 Aortic Valve 
 
114 
such as congestive HF, valve incompetence, and predisposition to recurrent IE are becoming 
more important. Moreover, the focus has shifted away from infections of native valves to 
endocarditis of prosthetic valves in the elderly and to endocarditis in users of injected drugs. 
Effective therapy has become progressively more difficult to achieve because of the 
proliferation of implanted biomechanical devices and the rise in the number of resistant 
organisms. 
Endocarditis has evolved into several variations, keeping it near the top of the list of 
diseases that must not be misdiagnosed or overlooked. 
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